EndoFlos Emulgel

EndoFlos is an innovative preparation that allows for an immediate reduction of vulvar and vaginal inflammation and/or pain, starting from the first applications.
  • Uses

It can be recommended in all cases of:

  • Vulvovaginitis: inflammation of the vagina and vulva
  • Dysmenorrhea: uterine pain that occurs during the menstrual period
  • Dyspareunia: genital pain experienced during sexual intercourse
  • Vulvodynia: pain associated with sexual dysfunction.
  • How to use

Apply one dose each evening for 7 days before the menstrual cycle, filling the applicator with gel entirely.

  • Active ingredients
  • Ibuprofen
  • Zantalene
  • N-acetylcysteine
  • Rutin
  • Chondroitin sulfate

Thanks to its active ingredients, it can also be recommended for a massage with relaxing, toning, and protective effects.

It is a well-known substance in literature that inhibits the production of prostaglandins, molecules involved in inflammatory processes. In particular, ibuprofen blocks the activity of the cyclooxygenase enzymes Cox-1 and Cox-2. Due to its anti-inflammatory and analgesic properties, ibuprofen is used to alleviate menstrual cramps, headaches, and neuralgia. When taken orally, it is contraindicated in cases of renal insufficiency, liver diseases, and gastrointestinal disorders (such as gastritis, ulcers, and bleeding hemorrhoids), respiratory diseases, and allergic asthma. When used topically, it does not present particular side effects and acts quickly to reduce pain in the affected area.
Zantalene is a natural active ingredient consisting of a lipophilic solution containing about 20% CO2 extract derived from the peels of Zanthoxylum Bungeanum fruits, a widely distributed perennial plant in Asia extensively used in traditional medicine and Chinese gastronomic tradition. Its main properties include a soothing and calming effect, reduction of skin sensitivity, and alleviation of itching sensation.
Due to its antioxidant properties, N-acetylcysteine helps protect DNA, cells, tissues, and organs from damage, inflammation, and harmful substances. NAC can be useful as a support to standard therapy to combat various disorders caused by oxidative stress, including infertility.
Rutin is a bioflavonoid found in numerous plants, including those in the Rutaceae family, which gives the substance its name. Plants with higher amounts of rutin include Japanese pagoda tree buds (Sophora japonica), leaves of a type of eucalyptus (Eucalyptus macrorhyncha), and buckwheat leaves (Fagopyrum esculentum). Its most well-known quality is the ability to improve the physiological permeability of capillaries, preventing the formation of edema. It appears to promote the trophism and elasticity of capillaries, improving circulation and counteracting bleeding due to its antiplatelet and antithrombotic properties. Numerous studies have also highlighted its antioxidant properties, capable of providing protective action for the body’s cells against the harmful effects of free radicals.
Chondroitin is a high molecular weight polysaccharide, meaning it is a long chain composed of sugar molecules. Specifically, it consists of alternating sequences of D-glucuronate molecules and residues of N-acetyl-D-galactosamine-4/6-sulfate. Its ability to alleviate pain, especially in joints, is well recognized. It is safe and well-tolerated.
  • Why EndoFlos Emulgel?

The emblematic symptom of endometriosis is pain. The initial dysmenorrhea caused by endometriosis quickly transforms into severe pelvic pain, which then becomes chronic. This pain can reach levels that become debilitating, compromising the quality of daily life and tends to worsen over time. Common comorbidities include fatigue, gastrointestinal symptoms, pain during defecation, especially during menstruation, dysuria, headache, nausea, and dyspareunia. The pain consumes vital energy, leaving the woman fatigued and depressed. The state of chronic inflammation associated with endometriosis involves:

– Hyperactivation of “mast cells,” which not only produce inflammation factors but also the nerve growth factor (NGF), leading to the proliferation of pain nerve fibers and a shift from nociceptive to neuropathic pain.
– Hyperactivation of the pain system, resulting in increased production of pain signals traveling to the brain, recruitment of normally silent pain fibers called “A delta” and “C,” cross-talk between pain fibers in nearby organs, explaining the progressive spread of pain throughout the pelvis and to organs such as the bladder, intestines, rectum, etc., and lowering the central pain threshold.
– Hyperactivation of the muscular system, with painful tensions in both the pelvis and generalized areas, causing antalgic postural alterations.

This involvement of multiple systems and associated comorbidities require a multimodal therapeutic approach, not limited to menstrual cycle suppression but capable of simultaneously reducing the various hyperactivations contributing to the development and maintenance of chronic pelvic pain.

Medical therapy for endometriosis aims primarily to reduce pain. The first-line drugs are NSAIDs (non-steroidal anti-inflammatory drugs), which, when administered orally continuously, can have numerous side effects.

The most appropriate choice for a comprehensive therapy that acts on different components of pain, achieving reductions in painful symptoms to restore quality of life, involves active principles that control inflammation, modulate non-menstrual pelvic pain, and reduce the use of oral analgesic drugs.

EndoFlos is an innovative preparation that allows for an immediate reduction of pain, even in the early applications, in cases of mild to moderate endometriosis.

  • Bibliography

1. Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med 2020;382:1244-56. doi:10.1056/NEJMra1810764
2. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010 Jun 24;362(25):2389-98
3. Becker CM, Bokor A, Heikinheimo O, et al, ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum
Reprod Open 2022;2022:hoac009. doi:10.1093/hropen/hoac009
4. Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W; European Society of Human Reproduction and Embryology. ESHRE guideline:
management of women with endometriosis. Hum Reprod. 2014 Mar;29(3):400-12
5. Saha R, Pettersson HJ, Svedberg P, et al: Heritability of endometriosis. Fertil Steril 104 (4):947–952, 2015. doi:
10.1016/j.fertnstert.2015.06.035 Epub 2015 Jul 22
6. Nnoaham KE, Hummelshoj L, Webster P, et al, World Endometriosis Research Foundation Global Study of Women’s Health
consortium. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil
Steril 2011;96:366373.e8. doi:10.1016/j.fertnstert.2011.05.090
7. https://www.sigo.it/wp-content/uploads/2017/09/Linee-Guida-Endometriosi-finale
8. Andrew W Horne, Stacey A Missmer Pathophysiology, diagnosis, and management of
endometriosis-DOI10.1136/bmj-2022-070750.BMJ 2022 Nov 14;379:e070750.doi: 10.1136/bmj-2022-070750